文献速递临床试验与 GCP

主动管理与期待管理对持续性不明位置妊娠成功转归的影响:ACT or NOT随机临床试验

Effect of an Active vs Expectant Management Strategy on Successful Resolution of Pregnancy Among Patients With a Persisting Pregnancy of Unknown Location: The ACT or NOT Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

该多中心随机临床试验纳入255例血流动力学稳定的持续性不明位置妊娠患者,随机分入期待管理、主动管理(宫腔清理后必要时甲氨蝶呤)或经验性甲氨蝶呤三组。结果显示主动管理组成功妊娠转归率显著高于期待管理组(51.5% vs 36.0%),经验性甲氨蝶呤非劣于宫腔清理后必要时甲氨蝶呤。

要点

  • 主动管理较期待管理提高不明位置妊娠成功转归率15.4%。
  • 经验性甲氨蝶呤非劣于宫腔清理后必要时甲氨蝶呤。
  • 三组最常见不良事件均为阴道出血(44.2%-52.9%)。

核心结论

  • 主动管理组成功妊娠转归率显著高于期待管理组(51.5% vs 36.0%)。
  • 经验性甲氨蝶呤非劣于宫腔清理后必要时甲氨蝶呤(54.9% vs 48.3%)。

研究设计与样本

  • 多中心随机临床试验,2014年7月25日至2019年6月4日在美国12个医学中心招募255例血流动力学稳定的持续性不明位置妊娠患者。
  • 按1:1:1随机分为期待管理组(n=86)、主动管理宫腔清理后必要时甲氨蝶呤组(n=87)和经验性甲氨蝶呤2剂方案组(n=82)。
  • 主要结局为无需改变初始策略的成功妊娠转归;253例(99.2%)完成试验。

主要发现

  • 主动管理组(n=169)成功妊娠转归率51.5%,期待管理组(n=86)为36.0%,差异15.4%(95% CI 2.8%至28.1%),率比1.43(95% CI 1.04至1.96)。
  • 经验性甲氨蝶呤组成功转归率54.9%,宫腔清理后必要时甲氨蝶呤组为48.3%,差异6.6%(单侧97.5% CI -8.4%至∞)。
  • 99例(39%)拒绝随机分配并交叉:26.7%拒绝期待管理,48.3%拒绝宫腔清理,41.5%拒绝经验性甲氨蝶呤。
  • 三组最常见不良事件为阴道出血,发生率44.2%-52.9%。

临床怎么用

  • 对血流动力学稳定的持续性不明位置妊娠患者,可考虑主动管理以提高成功转归率。
  • 经验性甲氨蝶呤可作为主动管理策略之一,非劣于宫腔清理后必要时甲氨蝶呤。
  • 临床决策需结合患者意愿,因近四成患者拒绝随机分配策略。

局限性

  • 39%患者拒绝随机分配并交叉,可能影响结果解读。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Women with an early nonviable pregnancy of unknown location are at high risk of ectopic pregnancy and its inherent morbidity and mortality. Successful and timely resolution of the gestation, while minimizing unscheduled interventions, are important priorities. OBJECTIVE: To determine if active management is more effective in achieving pregnancy resolution than expectant management and whether the use of empirical methotrexate is noninferior to uterine evacuation followed by methotrexate if needed. DESIGN, SETTING, AND PARTICIPANTS: This multicenter randomized clinical trial recruited 255 hemodynamically stable women with a diagnosed persisting pregnancy of unknown location between July 25, 2014, and June 4, 2019, in 12 medical centers in the United States (final follow up, August 19, 2019). INTERVENTIONS: Eligible patients were randomized in a 1:1:1 ratio to expectant management (n = 86), active management with uterine evacuation followed by methotrexate if needed (n = 87), or active management with empirical methotrexate using a 2-dose protocol (n = 82). MAIN OUTCOMES AND MEASURES: The primary outcome was successful resolution of the pregnancy without change from initial strategy. The primary hypothesis tested for superiority of the active groups combined vs expectant management, and a secondary hypothesis tested for noninferiority of empirical methotrexate compared with uterine evacuation with methotrexate as needed using a noninferiority margin of -12%. RESULTS: Among 255 patients who were randomized (median age, 31 years; interquartile range, 27-36 years), 253 (99.2%) completed the trial. Ninety-nine patients (39%) declined their randomized allocation (26.7% declined expectant management, 48.3% declined uterine evacuation, and 41.5% declined empirical methotrexate) and crossed over to a different group. Compared with patients randomized to receive expectant management (n = 86), women randomized to receive active management (n = 169) were significantly more likely to experience successful pregnancy resolution without change in their initial management strategy (51.5% vs 36.0%; difference, 15.4% [95% CI, 2.8% to 28.1%]; rate ratio, 1.43 [95% CI, 1.04 to 1.96]). Among active management strategies, empirical methotrexate was noninferior to uterine evacuation followed by methotrexate if needed with regard to successful pregnancy resolution without change in management strategy (54.9% vs 48.3%; difference, 6.6% [1-sided 97.5% CI, -8.4% to ∞]). The most common adverse event was vaginal bleeding for all of the 3 management groups (44.2%-52.9%). CONCLUSIONS AND RELEVANCE: Among patients with a persisting pregnancy of unknown location, patients randomized to receive active management, compared with those randomized to receive expectant management, more frequently achieved successful pregnancy resolution without change from the initial management strategy. The substantial crossover between groups should be considered when interpreting the results. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02152696.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Barnhart KT, Hansen KR, Stephenson MD, et al. Effect of an Active vs Expectant Management Strategy on Successful Resolution of Pregnancy Among Patients With a Persisting Pregnancy of Unknown Location: The ACT or NOT Randomized Clinical Trial. JAMA. 2021. PMID: 34342619. doi:10.1001/jama.2021.10767

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。